A Study of DCR-STAT3 in Adults With Solid Tumors

An Open-label, Phase 1, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-STAT3 in Adults With Refractory Solid Tumors

This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.

Study Overview

• Status: Recruiting
• Conditions: Solid Tumor, Adult; Refractory Tumor
• Intervention / Treatment: Drug: DCR-STAT3

Detailed Description

The primary goal of this first-in-human study is to assess the safety and tolerability of DCR-STAT3 in adults with refractory solid tumors. Secondary study goals are to evaluate potential antitumor effects of STAT3 knockdown, as assessed by circulating blood biomarkers indicative of immune activation, as well as any direct impact on tumor size by appropriate imaging and RECIST 1.1 criteria. Antitumor effects will be evaluated for DCR-STAT3 as a monotherapy.

• Study Type: Interventional
• Enrollment (Estimated): 32
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Vinita Uttamsingh; Phone Number: 857-278-9860; Email: VIUT@novonordisk.com

Study Locations

• United States
  • Texas
    • Dallas, Texas, United States, 75039
      • Recruiting
      • Next Oncology
      • Contact: Shiraj Sen, MD PHD; Phone Number: 972-893-8800
    • San Antonio, Texas, United States, 78229
      • Recruiting
      • Next Oncology
      • Contact: Anthony Tolcher, MD; Phone Number: 210-580-9500

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age
• ≥ 18 years of age inclusive, at the time of signing the informed consent.

Type of Participant and Disease Characteristics

- Documented locally advanced or metastatic solid tumor malignancy or non-Hodgkin's lymphoma that is refractory to standard therapy known to provide clinical benefit for their condition or for which no standard therapy is available

• Demonstrated evidence of disease progression, via imaging, during or following standard therapy known to provide clinical benefit for their condition
• Demonstrated intolerance to standard therapy known to provide clinical benefit for their condition
• Measurable disease according to RECIST version 1.1 (as determined by CT or MRI)
• Malignancy not currently amenable to surgical intervention due to medical contraindication or non-resectability of the tumor
• ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months

Weight

- BMI ≥ 18 kg/m2

Sex

Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 24 weeks after the last dose of study intervention:

1. Refrain from donating sperm

   AND, either:

2. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
3. Must agree to use a male condom when having sexual intercourse with a WOCBP who is not currently pregnant

Female participants are eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:

1. Is not a WOCBP OR

2. Is a WOCBP and:

   is using a contraceptive method that is highly effective, with a failure rate of < 1%, as described in Section 10.4 during the study intervention period and for at least 24 weeks after the last dose of study intervention. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.

   must have a negative highly sensitive pregnancy test (serum as required by local regulations) on Day 1 of each cycle before the first dose of study intervention

   Exclusion Criteria:

   Prior/Concomitant Therapy

   - Other concurrent (within 28 days of Day 1, Cycle 1) chemotherapy, immunotherapy, or radiotherapy. Note that hormonal therapy (e.g., tamoxifen, LHRH agonists) is allowed.

   - Requirement for palliative radiotherapy to lesions that are defined as target lesions by RECIST version 1.1 criteria at the time of study entry

   • Continued compromise or inadequate recovery from a prior anti-neoplastic therapy
   • Known hypersensitivity to any of the components of DCR-STAT3
   • Long-term immunosuppressive therapy

   Prior/Concurrent Clinical Study Experience

   • Treatment with investigational therapy(ies) within 5 half-lives of the investigational therapy prior to the first scheduled day of dosing with DCR-STAT3, or 4 weeks if the half-life of the investigational agent is not known

   Diagnostic assessments - Seropositive for antibodies to HIV, HBV, or HCV at Screening (historical testing may be used if performed within the 3 months prior to screening). NOTE: In participants with previous treatment for hepatitis C with direct-acting HCV medication and seropositivity for HCV, or in participants with prior infection and spontaneous resolution, HCV RNA must be undetectable (at least 2 negative HCV RNA tests at least 12 weeks apart), and the HCV infection must have been resolved or cured > 3 years prior to initial dosing with the investigational medication.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DCR-STAT3	Drug: DCR-STAT3; DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events and dose limiting toxicities	safety and tolerability	Cycle 1 (8 weeks)
Severity of adverse events	measured according to CTCAE 5.0 criteria	Cycle 1 (8 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic (AUC)	Area under the plasma concentration versus time curve	Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks)
Pharmacokinetic (Urine)	Urinary excretion	Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks)

Collaborators and Investigators

• Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
• Investigators: Study Director: John Hanrahan, MD MPH, Dicerna Phamaceuticals, a Novo Nordisk Company

Study record dates

Study Major Dates

• Study Start (Actual): August 14, 2023
• Primary Completion (Estimated): July 1, 2025
• Study Completion (Estimated): July 1, 2025

Study Registration Dates

• First Submitted: September 28, 2023
• First Submitted That Met QC Criteria: October 21, 2023
• First Posted (Actual): October 24, 2023

Study Record Updates

• Last Update Posted (Actual): October 24, 2023
• Last Update Submitted That Met QC Criteria: October 21, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: DCR-STAT3-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No